T1	PROC 44 54	Evaluación
#1	AnnotatorNotes T1	C1261322; Evaluation procedure; Health Care Activity
T2	CHEM 70 81	Metotrexato
#2	AnnotatorNotes T2	C0025677; methotrexate; Organic Chemical · Pharmacologic Substance
T3	CHEM 101 111	etanercept
#3	AnnotatorNotes T3	C0717758; etanercept; Amino Acid, Peptide, or Protein · Pharmacologic Substance
T4	CHEM 114 125	Metotrexato
#4	AnnotatorNotes T4	C0025677; methotrexate; Organic Chemical · Pharmacologic Substance
T5	DISO 143 162	artritis reumatoide
#5	AnnotatorNotes T5	C0003873; Rheumatoid Arthritis; Disease or Syndrome
T6	PROC 180 191	tratamiento
#6	AnnotatorNotes T6	C0087111; Therapeutic procedure; Therapeutic or Preventive Procedure
T7	CHEM 209 220	Metotrexato
#7	AnnotatorNotes T7	C0025677; methotrexate; Organic Chemical · Pharmacologic Substance
T8	PROC 242 275	Estudio aleatorizado y controlado
#8	AnnotatorNotes T8	C0206035; Controlled Clinical Trials, Randomized; Research Activity
T9	CHEM 291 302	metotrexato
#9	AnnotatorNotes T9	C0025677; methotrexate; Organic Chemical · Pharmacologic Substance
T10	CHEM 304 307	MTX
#10	AnnotatorNotes T10	C0025677; methotrexate; Organic Chemical · Pharmacologic Substance
T11	CHEM 328 338	etanercept
#11	AnnotatorNotes T11	C0717758; etanercept; Amino Acid, Peptide, or Protein · Pharmacologic Substance
T12	CHEM 341 344	MTX
#12	AnnotatorNotes T12	C0025677; methotrexate; Organic Chemical · Pharmacologic Substance
T13	DISO 362 381	artritis reumatoide
#13	AnnotatorNotes T13	C0003873; Rheumatoid Arthritis; Disease or Syndrome
T14	DISO 383 385	AR
#14	AnnotatorNotes T14	C0003873; Rheumatoid Arthritis; Disease or Syndrome
T15	PROC 444 455	tratamiento
#15	AnnotatorNotes T15	C0087111; Therapeutic procedure; Therapeutic or Preventive Procedure
T16	CHEM 473 476	MTX
#16	AnnotatorNotes T16	C0025677; methotrexate; Organic Chemical · Pharmacologic Substance
T17	DISO 500 519	Artritis Reumatoide
#17	AnnotatorNotes T17	C0003873; Rheumatoid Arthritis; Disease or Syndrome
T18	PROC 546 557	Diagnóstico
#18	AnnotatorNotes T18	C0011900; Diagnosis; Diagnostic Procedure
T19	DISO 561 580	artritis reumatoide
#19	AnnotatorNotes T19	C0003873; Rheumatoid Arthritis; Disease or Syndrome
T20	PROC 621 641	Tratamiento continuo
T21	CHEM 646 657	metotrexato
#20	AnnotatorNotes T21	C0025677; methotrexate; Organic Chemical · Pharmacologic Substance
T22	DISO 915 925	Enfermedad
#21	AnnotatorNotes T22	C0012634; Disease; Disease or Syndrome
T23	DISO 966 990	articulaciones hinchadas
#22	AnnotatorNotes T23	C0152031; Joint swelling; Finding
T24	ANAT 1001 1015	articulaciones
#23	AnnotatorNotes T24	C0022417; Joints; Body Space or Junction | C1269611; Entire joint; Body Space or Junction
T25	DISO 1001 1030	articulaciones hipersensibles
T26	PROC 1034 1074	proteína C reactiva de alta sensibilidad
T27	CHEM 1171 1188	corticoesteroides
#24	AnnotatorNotes T27	C0001617; Adrenal Cortex Hormones; Hormone · Organic Chemical · Pharmacologic Substance
T28	CHEM 1289 1306	corticoesteroides
#25	AnnotatorNotes T28	C0001617; Adrenal Cortex Hormones; Hormone · Organic Chemical · Pharmacologic Substance
T29	CHEM 1353 1363	prednisona
#26	AnnotatorNotes T29	C0032952; prednisone; Hormone · Organic Chemical · Pharmacologic Substance
T30	PROC 1460 1471	Tratamiento
#27	AnnotatorNotes T30	C0087111; Therapeutic procedure; Therapeutic or Preventive Procedure
T31	CHEM 1488 1507	inhibidor del FNT-α
T32	CHEM 1516 1592	fármacos biológicos antirreumáticos modificadores del curso de la enfermedad
#28	AnnotatorNotes T32	C4055380; Biologic Disease-Modifying Antirheumatic Drug; Pharmacologic Substance
T33	CHEM 1594 1599	DMARD
#29	AnnotatorNotes T33	C0242708; Antirheumatic Drugs, Disease-Modifying; Pharmacologic Substance
T34	CHEM 1614 1641	inhibidores de Janus cinasa
T35	CHEM 1648 1659	tofacitinib
#30	AnnotatorNotes T35	C2930696; tofacitinib; Organic Chemical · Pharmacologic Substance
T36	CHEM 58 67	Sarilumab
#31	AnnotatorNotes T36	C3885145; sarilumab; Amino Acid, Peptide, or Protein · Immunologic Factor · Pharmacologic Substance
T37	CHEM 196 206	adalimumab
#32	AnnotatorNotes T37	C1122087; adalimumab; Amino Acid, Peptide, or Protein · Immunologic Factor · Pharmacologic Substance
T38	CHEM 279 288	sarilumab
#33	AnnotatorNotes T38	C3885145; sarilumab; Amino Acid, Peptide, or Protein · Immunologic Factor · Pharmacologic Substance
T39	CHEM 460 470	adalimumab
#34	AnnotatorNotes T39	C1122087; adalimumab; Amino Acid, Peptide, or Protein · Immunologic Factor · Pharmacologic Substance
T40	ANAT 966 980	articulaciones
#35	AnnotatorNotes T40	C0022417; Joints; Body Space or Junction | C1269611; Entire joint; Body Space or Junction
T41	CHEM 1034 1044	proteína C
#36	AnnotatorNotes T41	C0033621; protein C; Amino Acid, Peptide, or Protein · Biologically Active Substance · Pharmacologic Substance
T42	PROC 1076 1082	PCR-as
#37	AnnotatorNotes T42	C4763419; High Sensitivity C-Reactive Protein Measurement; Laboratory Procedure
T43	PROC 1153 1224	Administración de corticoesteroides por vía parenteral o intraarticular
T44	Date 12 16	2012
T45	LIVB 129 138	pacientes
#38	AnnotatorNotes T45	C0030705; Patients; Patient or Disabled Group
T46	LIVB 348 357	pacientes
#39	AnnotatorNotes T46	C0030705; Patients; Patient or Disabled Group
T47	Duration 433 440	4 meses
T48	Dose 658 674	entre 10 y 25 mg
T49	Frequency 674 681	/semana
T51	Duration 785 804	al menos 12 semanas
T52	Dose 843 857	dosis estables
T53	Duration 866 888	al menos las 8 semanas
T58	Age 1134 1152	inferior a 18 años
T59	Route 1193 1207	vía parenteral
T60	Route 1210 1224	intraarticular
T61	Duration 1228 1241	las 4 semanas
T62	Route 1311 1319	vía oral
#40	AnnotatorNotes T62	C1527415; Oral Route of Drug administration; Functional Concept
T64	Dose 1323 1349	una dosis superior a 10 mg
T65	Frequency 1378 1384	al día
T66	Duration 1410 1423	las 4 semanas
T69	Duration 581 607	superior o igual a 3 meses
T50	PROC 1388 1406	cambio en la dosis
#41	AnnotatorNotes T50	C2064702; modify drug dosage; Health Care Activity
T54	DISO 1582 1592	enfermedad
#42	AnnotatorNotes T54	C0012634; Disease; Disease or Syndrome
T55	PROC 908 914	visita
#43	AnnotatorNotes T55	C1512346; Patient Visit; Health Care Activity
T56	PROC 1258 1277	visita de selección
#44	AnnotatorNotes T56	C1710477; Trial Screening; Research Activity + C1512346; Patient Visit; Health Care Activity
T57	PROC 817 836	visita de selección
#45	AnnotatorNotes T57	C1710477; Trial Screening; Research Activity + C1512346; Patient Visit; Health Care Activity
T63	PROC 1440 1459	visita de selección
#46	AnnotatorNotes T63	C1710477; Trial Screening; Research Activity + C1512346; Patient Visit; Health Care Activity
A1	Status T30 History_of
A2	Status T31 History_of
A3	Status T32 History_of
A4	Status T33 History_of
A5	Status T34 History_of
A6	Status T35 History_of
#47	AnnotatorNotes T26	C4763419; High Sensitivity C-Reactive Protein Measurement; Laboratory Procedure
#48	AnnotatorNotes T60	C1522204; Intraarticular Route of Drug Administration; Functional Concept
#49	AnnotatorNotes T59	C1518896; Parenteral Route of Drug Administration; Functional Concept
#50	AnnotatorNotes T31	C3653350; Tumor necrosis factor alpha (TNF-alpha) inhibitors; Pharmacologic Substance 
#51	AnnotatorNotes T34	C3854325; Janus kinase inhibitor; Pharmacologic Substance 
R1	Combined_with Arg1:T36 Arg2:T2	
R2	Combined_with Arg1:T3 Arg2:T4	
R3	Experiences Arg1:T45 Arg2:T36	
R4	Experiences Arg1:T45 Arg2:T3	
R5	Experiences Arg1:T45 Arg2:T5	
R6	Experiences Arg1:T45 Arg2:T6	
R7	Used_for Arg1:T37 Arg2:T6	
R8	Combined_with Arg1:T37 Arg2:T7	
T67	Observation 167 191	respuesta al tratamiento
#52	AnnotatorNotes T67	C1319171; Medication response; Finding
R9	Overlap Arg1:T5 Arg2:T67	
R10	Overlap Arg1:T67 Arg2:T6	
R11	Experiences Arg1:T45 Arg2:T67	
R12	Combined_with Arg1:T38 Arg2:T9	
R13	Combined_with Arg1:T38 Arg2:T10	
R14	Combined_with Arg1:T11 Arg2:T12	
R15	Experiences Arg1:T46 Arg2:T38	
R17	Experiences Arg1:T46 Arg2:T11	
R18	Experiences Arg1:T46 Arg2:T13	
R19	Experiences Arg1:T46 Arg2:T14	
T68	Observation 410 430	respuesta inadecuada
#53	AnnotatorNotes T68	C0858218; Inappropriate drug response; Finding
R20	Overlap Arg1:T68 Arg2:T15	
R21	After Arg1:T68 Arg2:T47	
R22	Has_Duration_or_Interval Arg1:T39 Arg2:T47	
R23	Has_Duration_or_Interval Arg1:T16 Arg2:T47	
R24	Combined_with Arg1:T39 Arg2:T16	
R25	Used_for Arg1:T39 Arg2:T15	
R26	Before Arg1:T6 Arg2:T36	
R27	Before Arg1:T6 Arg2:T3	
R28	Before Arg1:T15 Arg2:T38	
R29	Before Arg1:T15 Arg2:T11	
R30	Has_Duration_or_Interval Arg1:T19 Arg2:T69	
R31	Used_for Arg1:T21 Arg2:T20	
R32	Has_Dose_or_Strength Arg1:T21 Arg2:T48	
R33	Has_Frequency Arg1:T21 Arg2:T49	
R34	Has_Duration_or_Interval Arg1:T21 Arg2:T51	
R35	Before Arg1:T20 Arg2:T57	
R36	Has_Dose_or_Strength Arg1:T21 Arg2:T52	
R37	Has_Duration_or_Interval Arg1:T52 Arg2:T53	
R38	Before Arg1:T52 Arg2:T55	
T70	Quantifier_or_Qualifier 949 959	al menos 6
R39	Has_Quantifier_or_Qualifier Arg1:T23 Arg2:T70	
R40	Location_of Arg1:T40 Arg2:T23	
T71	Quantifier_or_Qualifier 926 932	activa
#54	AnnotatorNotes T71	C0205177; Active; Qualitative Concept | C0679217; Active State; Idea or Concept
R41	Has_Quantifier_or_Qualifier Arg1:T22 Arg2:T71	
R42	Overlap Arg1:T22 Arg2:T23	
T72	Quantifier_or_Qualifier 993 994	8
R43	Has_Quantifier_or_Qualifier Arg1:T25 Arg2:T72	
R44	Overlap Arg1:T22 Arg2:T25	
R45	Location_of Arg1:T24 Arg2:T25	
#55	AnnotatorNotes T25	C0240094; Joint tenderness; Sign or Symptom
T73	Result_or_Value 1084 1102	superior a 10 mg/l
R46	Has_Result_or_Value Arg1:T26 Arg2:T73	
R47	Has_Result_or_Value Arg1:T42 Arg2:T73	
R54	Used_for Arg1:T27 Arg2:T43	
R55	Has_Route_or_Mode Arg1:T27 Arg2:T59	
R56	Has_Route_or_Mode Arg1:T27 Arg2:T60	
R57	Has_Duration_or_Interval Arg1:T27 Arg2:T61	
R58	Overlap Arg1:T43 Arg2:T56	
R59	Has_Route_or_Mode Arg1:T28 Arg2:T62	
R60	Has_Dose_or_Strength Arg1:T28 Arg2:T64	
R61	Has_Route_or_Mode Arg1:T29 Arg2:T62	
R62	Has_Dose_or_Strength Arg1:T29 Arg2:T64	
T74	CONC 1353 1363;1366 1377	prednisona equivalente
R63	Has_Frequency Arg1:T29 Arg2:T65	
R64	Has_Frequency Arg1:T28 Arg2:T65	
R65	Used_for Arg1:T28 Arg2:T50	
R66	Used_for Arg1:T29 Arg2:T50	
R67	Overlap Arg1:T50 Arg2:T66	
R68	Before Arg1:T50 Arg2:T63	
R69	Before Arg1:T28 Arg2:T63	
R70	Before Arg1:T29 Arg2:T63	
R71	Before Arg1:T74 Arg2:T63	
R72	Used_for Arg1:T31 Arg2:T30	
R73	Used_for Arg1:T32 Arg2:T30	
R74	Used_for Arg1:T33 Arg2:T30	
R75	Used_for Arg1:T34 Arg2:T30	
R76	Used_for Arg1:T35 Arg2:T30	
R16	Overlap Arg1:T13 Arg2:T68	
R77	Overlap Arg1:T14 Arg2:T68	
R78	Experiences Arg1:T46 Arg2:T68	
R79	Experiences Arg1:T46 Arg2:T15	
R80	Before Arg1:T52 Arg2:T57	
R81	Before Arg1:T20 Arg2:T55	
R82	Overlap Arg1:T23 Arg2:T25	
T75	Quantifier_or_Qualifier 1601 1611	biológicos
#56	AnnotatorNotes T75	C0205460; biological; Qualitative Concept
A7	Status T75 History_of
R48	Has_Quantifier_or_Qualifier Arg1:T33 Arg2:T75	
R49	Has_Quantifier_or_Qualifier Arg1:T32 Arg2:T75	
A8	Experiencer T45 Patient
A9	Experiencer T46 Patient
